Impact News +++ Eutelsat-Aktie fällt erneut deutlich: Anleger nehmen zweiten Tag in Folge Gewinne mit (Finanzen.net) +++ EUTELSAT Aktie +3,63%

SCPHARMACEUTICALS Aktie

>Aktienkurs

3.386 EUR (Tradegate)

Ask: 3.432 EUR / 3000 Stück

Bid: 3.34 EUR / 3000 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 8 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -1,8%

1 Monat: +16,0%

3 Monate: +21,6%

6 Monate: +3,8%

1 Jahr: -10,1%

laufendes Jahr: +4,5%

>SCPHARMACEUTICALS Aktie

Name:

SCPHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8106481059 / A2H7XD

Symbol/ Ticker:

2SX (Frankfurt) / SCPH (NASDAQ)

Kürzel:

FRA:2SX, ETR:2SX, 2SX:GR, NASDAQ:SCPH

Index:

Webseite:

https://www.scpharmaceuti..

Marktkapitalisierung:

183.49 Mio. EUR

Umsatz:

36.35 Mio. EUR

EBITDA:

-57.71 Mio. EUR

Gewinn je Aktie:

-1.446 EUR

Schulden:

45.33 Mio. EUR

Liquide Mittel:

50.13 Mio. EUR

Umsatz-/ Gewinnwachstum:

92.6% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

4.57 / 29.09 / -

Gewinnm./ Eigenkapitalr.:

-216.24% / -934.02%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

SCPHARMACEUTICALS, SC PHARMACEUTICALS

Letzte Datenerhebung:

25.06.25

>Eigentümer

Aktien: 52.79 Mio. St.

f.h. Aktien: 31.63 Mio. St.

Insider Eigner: 6.08%

Instit. Eigner: 76.64%

Leerverk. Aktien: 4.15%

>Peer Group

ATYR

CONTEXT THERAPEUTICS

CONVATEC ADR

DURECT

ELICIO

FULGENT GENETICS

INFUSYSTEM

MYOMO

SEMLER SCIENTIFIC

ZIMVIE

>Chart & Kurs - NASDAQ

>Alle News

15.05.25 - 06:21	ScPharmaceuticals targets CKD launch and rising Medicare fill rates to accelerate FUROSCIX growth trajectory (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

15.05.25 - 01:00	ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
	scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -25.93% and 3.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

14.05.25 - 22:06	scPharmaceuticals GAAP EPS of -$0.37 misses by $0.07, revenue of $11.75M beats by $0.12M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:03	scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025...

07.05.25 - 22:06	scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 (GlobeNewswire EN)
	Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET...

01.05.25 - 22:03	scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire EN)
	BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences:...

20.03.25 - 00:18	ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.03.25 - 00:00	ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 12.50% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

19.03.25 - 21:18	scPharmaceuticals GAAP EPS of -$0.35 beats by $0.03, revenue of $12.2M beats by $0.02M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.03.25 - 21:03	scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire EN)
	scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million...

12.03.25 - 21:03	scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 (GlobeNewswire EN)
	Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET...

06.03.25 - 22:03	scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease (GlobeNewswire EN)
	FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome...

05.03.25 - 17:30	ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
	ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

26.02.25 - 22:03	scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire EN)
	BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences:...

05.02.25 - 22:03

scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire EN)

BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET....

10.01.25 - 16:06	scPharmaceuticals reports preliminary Q4 numbers (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.01.25 - 14:03	scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire EN)
	Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range...

14.11.24 - 00:48	ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
	scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -23.33% and 7.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?...

13.11.24 - 22:12	scPharmaceuticals GAAP EPS of -$0.75 misses by $0.45, revenue of $10.02M misses by $0.78M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.11.24 - 22:03	scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire EN)
	Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram